Vaxart Inc
Change company Symbol lookup
Select an option...
VXRT Vaxart Inc
CIHHF China Merchants Bank Co Ltd
BBY Best Buy Co Inc
BDGE Bridge Bancorp Inc
FFIC Flushing Financial Corp
TSC TriState Capital Holdings Inc
CSQPF Cervus Equipment Corp
IMXI International Money Express Inc
MDCO Medicines Co
TVETF Traverse Energy Ltd
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Closing Price
$2.10
Day's Change
0.02 (0.96%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.35
Day's Low
2.00
Volume
(Light)
Volume:
496,470

10-day average volume:
3,555,464
496,470

Apple's sales warning could hurt Best Buy analysts say, price target slashed

3:37 pm ET January 3, 2019 (MarketWatch)
Print

UBS slashed Best Buy Co Inc.'s (BBY) price target to $57 from $70 after news that Apple Inc. (AAPL) was cutting its sales forecast (http://www.marketwatch.com/story/apple-stock-sinks-as-wall-street-cuts-target-to-14-month-low-after-darkest-day-in-iphone-era-2019-01-03). Analysts think the consumer electronics retailer's earnings are closely tied to sales of Apple products. "While Apple noted that its shortfall mostly occurred in China, the announcement highlights the risk for Best Buy from the fortunes of its key vendor partners," UBS wrote. UBS estimates that Apple products account for 15% to 20% of Best Buy sales. Moreover, Apple products are now available on Amazon.com Inc. (AMZN) and at Costco Wholesale Corp. (COST). "Expanded distribution means that it will be harder for Best Buy to sustain its share gains," UBS said. Best Buy shares took a tumble a couple of weeks ago (http://www.marketwatch.com/story/best-buy-shares-fall-after-reports-of-sluggish-holiday-season-iphone-sales-2018-12-13) on reports of sluggish iPhone sales. The retailer's stock is down 1.7% in Thursday trading, and down 23% for the last year. The S&P 500 index is off 9.5% for the past 12 months.

-Tonya Garcia; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 03, 2019 15:37 ET (20:37 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.